NDLI: Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Please wait, while we are loading the content...

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Content Provider	Scilit
Author	Zeidan, Amer M. Lee, Ju-Whei Prebet, Thomas Greenberg, Peter Sun, Zhuoxin Juckett, Mark Smith, Mitchell R. Paietta, Elisabeth Gabrilove, Janice Erba, Harry P. Tallman, Martin S. Gore, Steven D.
Copyright Year	2014
Description	Journal: British Journal of Haematology The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299460/pdf
Ending Page	359
Page Count	8
Starting Page	352
e-ISSN	13652141
DOI	10.1111/bjh.12884
Journal	British Journal of Haematology
Issue Number	3
Volume Number	166
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2014-04-09
Access Restriction	Open
Subject Keyword	Journal: British Journal of Haematology French Prognostic Scoring System Myelodysplastic Syndromes Prognostic Models Revised International Prognostic Scoring System
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Comparison of the Prognostic Utility of the Revised International Prognostic Scoring System and the French Prognostic Scoring System in Azacitidine-Treated Patients with Myelodysplastic Syndromes

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine.

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting.

Platelet mass has prognostic value in patients with myelodysplastic syndromes

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Similar Documents

Comparison of the Prognostic Utility of the Revised International Prognostic Scoring System and the French Prognostic Scoring System in Azacitidine-Treated Patients with Myelodysplastic Syndromes

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine.

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting.

Platelet mass has prognostic value in patients with myelodysplastic syndromes

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes